Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 197

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria

Open access
Geisinger, Edward, Isberg, Ralph R. · 2017 · The Journal of Infectious Diseases

Abstract

Diseases caused by antibiotic-resistant bacteria in hospitals are the outcome of complex relationships between several dynamic factors, including bacterial pathogenicity, the fitness costs of resistance in the human host, and selective forces resulting from interventions such as antibiotic therapy. The emergence and fate of mutations that drive antibiotic resistance are governed by these interactions. In this review, we will examine how different forms of antibiotic resistance modulate bacterial fitness and virulence potential, thus influencing the ability of pathogens to evolve in the context of nosocomial infections. We will focus on 3 important multidrug-resistant pathogens that are notoriously problematic in hospitals: Pseudomonas aeruginosa, Acinetobacter baumannii, and Staphylococcus aureus. An understanding of how antibiotic resistance mutations shape the pathobiology of multidrug-resistant infections has the potential to drive novel strategies that can control the development and spread of drug resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jiw402

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 102

  1. Andersson, 2010, Antibiotic resistance and its cost: is it possible to reverse resistance?, Nat Rev Microbiol, 8, 260, 10.1038/nrmicro2319 · DOI · Paper page
  2. Luo, 2005, Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure, Proc Natl Acad Sci USA, 102, 541, 10.1073/pnas.0408966102 · DOI
  3. Roux, 2015, Fitness cost of antibiotic susceptibility during bacterial infection, Sci Transl Med, 7, 297ra114, 10.1126/scitranslmed.aab1621 · DOI
  4. Skurnik, 2013, Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing, Proc Natl Acad Sci USA, 110, 20747, 10.1073/pnas.1221552110 · DOI
  5. Ballok, 2013, Pouring salt on a wound: Pseudomonas aeruginosa virulence factors alter Na+ and Cl- flux in the lung, J Bacteriol, 195, 4013, 10.1128/JB.00339-13 · DOI
  6. Boucher, 2009, Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America, Clin Infect Dis, 48, 1, 10.1086/595011 · DOI · Paper page
  7. Lister, 2009, Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms, Clin Microbiol Rev, 22, 582, 10.1128/CMR.00040-09 · DOI · Paper page
  8. Li, 2015, The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria, Clin Microbiol Rev, 28, 337, 10.1128/CMR.00117-14 · DOI · Paper page
  9. Hocquet, 2007, MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin, Antimicrob Agents Chemother, 51, 1582, 10.1128/AAC.01334-06 · DOI
  10. Salunkhe, 2005, A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance, J Bacteriol, 187, 4908, 10.1128/JB.187.14.4908-4920.2005 · DOI · Paper page
  11. Xavier, 2010, Efflux pumps expression and its association with porin down-regulation and beta-lactamase production among Pseudomonas aeruginosa causing bloodstream infections in Brazil, BMC Microbiol, 10, 217, 10.1186/1471-2180-10-217 · DOI
  12. Jalal, 2000, Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients, Antimicrob Agents Chemother, 44, 710, 10.1128/AAC.44.3.710-712.2000 · DOI · Paper page
  13. Jeannot, 2008, Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump, Antimicrob Agents Chemother, 52, 2455, 10.1128/AAC.01107-07 · DOI · Paper page
  14. Wolter, 2009, Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype, J Antimicrob Chemother, 64, 294, 10.1093/jac/dkp185 · doi:10.1093/jac/dkp185
  15. Sanchez, 2002, Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants, J Antimicrob Chemother, 50, 657, 10.1093/jac/dkf185 · DOI · Paper page
  16. Abdelraouf, 2011, Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa, J Antimicrob Chemother, 66, 1311, 10.1093/jac/dkr105 · DOI
  17. Hocquet, 2003, Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone, Antimicrob Agents Chemother, 47, 1887, 10.1128/AAC.47.6.1887-1894.2003 · DOI
  18. Martinez-Ramos, 2014, Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing, Antimicrob Agents Chemother, 58, 2426, 10.1128/AAC.02012-13 · doi:10.1128/aac.02012-13
  19. Cosson, 2002, Pseudomonas aeruginosa virulence analyzed in a Dictyostelium discoideum host system, J Bacteriol, 184, 3027, 10.1128/JB.184.11.3027-3033.2002 · DOI · Paper page
  20. Olivares, 2012, Overproduction of the multidrug efflux pump MexEF-OprN does not impair Pseudomonas aeruginosa fitness in competition tests, but produces specific changes in bacterial regulatory networks, Environ Microbiol, 14, 1968, 10.1111/j.1462-2920.2012.02727.x · DOI
  21. Stickland, 2010, Mutation of nfxB causes global changes in the physiology and metabolism of Pseudomonas aeruginosa, J Proteome Res, 9, 2957, 10.1021/pr9011415 · DOI
  22. Linares, 2005, Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa, J Bacteriol, 187, 1384, 10.1128/JB.187.4.1384-1391.2005 · DOI · Paper page
  23. Kohler, 2001, Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in Pseudomonas aeruginosa, J Bacteriol, 183, 5213, 10.1128/JB.183.18.5213-5222.2001 · DOI · Paper page
  24. Lamarche, 2011, MexEF-OprN efflux pump exports the Pseudomonas quinolone signal (PQS) precursor HHQ (4-hydroxy-2-heptylquinoline), PLoS One, 6, e24310, 10.1371/journal.pone.0024310 · DOI
  25. Hirakata, 2002, Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa, J Exp Med, 196, 109, 10.1084/jem.20020005 · DOI · Paper page
  26. Mahajan-Miklos, 1999, Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa-Caenorhabditis elegans pathogenesis model, Cell, 96, 47, 10.1016/S0092-8674(00)80958-7 · DOI · Paper page
  27. Smith, 2006, Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients, Proc Natl Acad Sci USA, 103, 8487, 10.1073/pnas.0602138103 · DOI · Paper page
  28. Vettoretti, 2009, Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients, Antimicrob Agents Chemother, 53, 1987, 10.1128/AAC.01024-08 · doi:10.1128/aac.01024-08
  29. Hauser, 2011, Clinical significance of microbial infection and adaptation in cystic fibrosis, Clin Microbiol Rev, 24, 29, 10.1128/CMR.00036-10 · DOI · Paper page
  30. Trias, 1990, Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides, J Biol Chem, 265, 15680, 10.1016/S0021-9258(18)55452-1 · DOI · Paper page
  31. Trias, 1990, Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 34, 52, 10.1128/AAC.34.1.52 · DOI · Paper page
  32. Yoneyama, 1991, Cloning of the protein D2 gene of Pseudomonas aeruginosa and its functional expression in the imipenem-resistant host, FEBS Lett, 283, 177, 10.1016/0014-5793(91)80582-N · doi:10.1016/0014-5793(91)80582-n
  33. Riera, 2011, Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem, J Antimicrob Chemother, 66, 2022, 10.1093/jac/dkr232 · DOI · Paper page
  34. Cabot, 2011, Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study, Antimicrob Agents Chemother, 55, 1906, 10.1128/AAC.01645-10 · doi:10.1128/aac.01645-10
  35. Pena, 2012, Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections, Antimicrob Agents Chemother, 56, 1265, 10.1128/AAC.05991-11 · DOI
  36. Wolter, 2008, Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy, Clin Infect Dis, 46, e137, 10.1086/588484 · doi:10.1086/588484
  37. Bagge, 2002, Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD, Antimicrob Agents Chemother, 46, 3406, 10.1128/AAC.46.11.3406-3411.2002 · DOI
  38. Tam, 2007, Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa, Clin Microbiol Infect, 13, 413, 10.1111/j.1469-0691.2006.01674.x · DOI
  39. Moya, 2009, Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein, PLoS Pathog, 5, e1000353, 10.1371/journal.ppat.1000353 · DOI · Paper page
  40. Moya, 2008, Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 52, 3694, 10.1128/AAC.00172-08 · doi:10.1128/aac.00172-08
  41. Folkesson, 2005, Components of the peptidoglycan-recycling pathway modulate invasion and intracellular survival of Salmonella enterica serovar Typhimurium, Cell Microbiol, 7, 147, 10.1111/j.1462-5822.2004.00443.x · DOI
  42. Balasubramanian, 2012, The regulatory repertoire of Pseudomonas aeruginosa AmpC ss-lactamase regulator AmpR includes virulence genes, PLoS One, 7, e34067, 10.1371/journal.pone.0034067 · DOI
  43. Oliver, 2000, High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection, Science, 288, 1251, 10.1126/science.288.5469.1251 · DOI · Paper page
  44. Macia, 2005, Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections, Antimicrob Agents Chemother, 49, 3382, 10.1128/AAC.49.8.3382-3386.2005 · DOI · Paper page
  45. Perron, 2010, Hypermutability and compensatory adaptation in antibiotic-resistant bacteria, Am Nat, 176, 303, 10.1086/655217 · DOI
  46. Montanari, 2007, Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis, Microbiology, 153, 1445, 10.1099/mic.0.2006/003400-0 · doi:10.1099/mic.0.2006/003400-0
  47. Alcala-Franco, 2012, Antibiotic pressure compensates the biological cost associated with Pseudomonas aeruginosa hypermutable phenotypes in vitro and in a murine model of chronic airways infection, J Antimicrob Chemother, 67, 962, 10.1093/jac/dkr587 · DOI
  48. Jones, 2015, Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence, Clin Infect Dis, 61, 145, 10.1093/cid/civ225 · DOI
  49. Bruhn, 2015, Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia, J Infect Dis, 211, 1296
  50. Doi, 2015, Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options, Semin Respir Crit Care Med, 36, 85, 10.1055/s-0034-1398388 · DOI · Paper page
  51. Beceiro, 2011, Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system, Antimicrob Agents Chemother, 55, 3370, 10.1128/AAC.00079-11 · DOI · Paper page
  52. Pelletier, 2013, Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii, Antimicrob Agents Chemother, 57, 4831, 10.1128/AAC.00865-13 · DOI · Paper page
  53. Snitkin, 2013, Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment, Genome Res, 23, 1155, 10.1101/gr.154328.112 · DOI
  54. Hraiech, 2013, Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia, Antimicrob Agents Chemother, 57, 5120, 10.1128/AAC.00700-13 · doi:10.1128/aac.00700-13
  55. Lopez-Rojas, 2011, Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii, J Infect Dis, 203, 545, 10.1093/infdis/jiq086 · DOI
  56. Lopez-Rojas, 2013, Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness, Antimicrob Agents Chemother, 57, 4587, 10.1128/AAC.00543-13 · DOI
  57. Durante-Mangoni, 2015, Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii, Diagn Microbiol Infect Dis, 82, 222, 10.1016/j.diagmicrobio.2015.03.013 · DOI
  58. Wand, 2015, Retention of virulence following adaptation to colistin in Acinetobacter baumannii reflects the mechanism of resistance, J Antimicrob Chemother, 70, 2209, 10.1093/jac/dkv097 · doi:10.1093/jac/dkv097
  59. Napier, 2013, Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii, MBio, 4, e00021, 10.1128/mBio.00021-13 · DOI
  60. Beceiro, 2014, Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii, Antimicrob Agents Chemother, 58, 518, 10.1128/AAC.01597-13 · DOI · Paper page
  61. Moffatt, 2010, Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production, Antimicrob Agents Chemother, 54, 4971, 10.1128/AAC.00834-10 · DOI · Paper page
  62. Yoon, 2015, Contribution of resistance-nodulation-cell division efflux systems to antibiotic resistance and biofilm formation in Acinetobacter baumannii, MBio, 6, e00309, 10.1128/mBio.00309-15 · DOI · Paper page
  63. Rumbo, 2013, Contribution of efflux pumps, porins, and beta-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii, Antimicrob Agents Chemother, 57, 5247, 10.1128/AAC.00730-13 · DOI · Paper page
  64. Yoon, 2016, Contribution of the Ade resistance-nodulation-cell division-type efflux pumps to fitness and pathogenesis of Acinetobacter baumannii, MBio, 7, e00697, 10.1128/mBio.00697-16 · DOI
  65. Richmond, 2016, The Acinetobacter baumannii two-component system AdeRS regulates genes required for multidrug efflux, biofilm formation, and virulence in a strain-Specific manner, MBio, 7, e00430
  66. Gebhardt, 2015, Joint transcriptional control of virulence and resistance to antibiotic and environmental stress in Acinetobacter baumannii, MBio, 6, e01660, 10.1128/mBio.01660-15 · DOI
  67. Eijkelkamp, 2011, Investigation of the human pathogen Acinetobacter baumannii under iron limiting conditions, BMC Genomics, 12, 126, 10.1186/1471-2164-12-126 · DOI · Paper page
  68. Ezraty, 2013, Fe-S cluster biosynthesis controls uptake of aminoglycosides in a ROS-less death pathway, Science, 340, 1583, 10.1126/science.1238328 · DOI · Paper page
  69. Kreamer, 2015, The ferrous iron-responsive BqsRS two-component system activates genes that promote cationic stress tolerance, MBio, 6, e02549, 10.1128/mBio.02549-14 · DOI
  70. Oglesby-Sherrouse, 2014, The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa, Pathog Dis, 70, 307, 10.1111/2049-632X.12132 · DOI
  71. Tipton, 2015, Phase-variable control of multiple phenotypes in Acinetobacter baumannii strain AB5075, J Bacteriol, 197, 2593, 10.1128/JB.00188-15 · doi:10.1128/jb.00188-15
  72. Weber, 2015, A multidrug resistance plasmid contains the molecular switch for type VI secretion in Acinetobacter baumannii, Proc Natl Acad Sci USA, 112, 9442, 10.1073/pnas.1502966112 · DOI · Paper page
  73. Siempos, 2010, Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis, Shock, 33, 590, 10.1097/SHK.0b013e3181cc0418 · DOI
  74. Andersson, 2014, Microbiological effects of sublethal levels of antibiotics, Nat Rev Microbiol, 12, 465, 10.1038/nrmicro3270 · DOI · Paper page
  75. Geisinger, 2015, Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii, PLoS Pathog, 11, e1004691, 10.1371/journal.ppat.1004691 · DOI · Paper page
  76. Hood, 2010, Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations, Antimicrob Agents Chemother, 54, 1029, 10.1128/AAC.00963-09 · doi:10.1128/aac.00963-09
  77. Novick, 2008, Quorum sensing in staphylococci, Annu Rev Genet, 42, 541, 10.1146/annurev.genet.42.110807.091640 · DOI · Paper page
  78. Cameron, 2011, The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes, Clin Infect Dis, 53, 576, 10.1093/cid/cir473 · DOI
  79. Collins, 2010, Offsetting virulence and antibiotic resistance costs by MRSA, ISME J, 4, 577, 10.1038/ismej.2009.151 · DOI
  80. Lee, 2007, Fitness cost of staphylococcal cassette chromosome mec in methicillin-resistant Staphylococcus aureus by way of continuous culture, Antimicrob Agents Chemother, 51, 1497, 10.1128/AAC.01239-06 · DOI
  81. Day, 2012, Community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus virulence toward Caenorhabditis elegans compared, Virulence, 3, 576, 10.4161/viru.22120 · DOI
  82. Diep, 2008, The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus, J Infect Dis, 197, 1523, 10.1086/587907 · DOI · Paper page
  83. Rudkin, 2012, Methicillin resistance reduces the virulence of healthcare-associated methicillin-resistant Staphylococcus aureus by interfering with the agr quorum sensing system, J Infect Dis, 205, 798, 10.1093/infdis/jir845 · DOI · Paper page
  84. Kaito, 2011, Transcription and translation products of the cytolysin gene psm-mec on the mobile genetic element SCCmec regulate Staphylococcus aureus virulence, PLoS Pathog, 7, e1001267, 10.1371/journal.ppat.1001267 · DOI
  85. Queck, 2009, Mobile genetic element-encoded cytolysin connects virulence to methicillin resistance in MRSA, PLoS Pathog, 5, e1000533, 10.1371/journal.ppat.1000533 · DOI · Paper page
  86. Muller, 2015, Poorly cross-Linked peptidoglycan in MRSA due to mecA induction activates the inflammasome and exacerbates immunopathology, Cell Host Microbe, 18, 604, 10.1016/j.chom.2015.10.011 · DOI
  87. Peleg, 2009, Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection, J Infect Dis, 199, 532, 10.1086/596511 · DOI · Paper page
  88. Majcherczyk, 2008, Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis, Microb Pathog, 45, 408, 10.1016/j.micpath.2008.09.003 · DOI
  89. Burnie, 2000, Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin, Clin Infect Dis, 31, 684, 10.1086/314035 · DOI
  90. Howden, 2008, Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia, BMC Microbiol, 8, 39, 10.1186/1471-2180-8-39 · DOI
  91. Cameron, 2012, Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus, J Infect Dis, 205, 1677, 10.1093/infdis/jis252 · DOI
  92. Renzoni, 2011, Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus, PLoS One, 6, e21577, 10.1371/journal.pone.0021577 · DOI
  93. Burnside, 2010, Regulation of hemolysin expression and virulence of Staphylococcus aureus by a serine/threonine kinase and phosphatase, PLoS One, 5, e11071, 10.1371/journal.pone.0011071 · DOI · Paper page
  94. Sun, 2012, Protein cysteine phosphorylation of SarA/MgrA family transcriptional regulators mediates bacterial virulence and antibiotic resistance, Proc Natl Acad Sci USA, 109, 15461, 10.1073/pnas.1205952109 · DOI · Paper page
  95. Cheung, 2008, The SarA protein family of Staphylococcus aureus, Int J Biochem Cell Biol, 40, 355, 10.1016/j.biocel.2007.10.032 · DOI · Paper page
  96. Gao, 2013, The RpoB H481Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus, J Infect Dis, 207, 929, 10.1093/infdis/jis772 · DOI
  97. Besier, 2007, Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease, J Clin Microbiol, 45, 168, 10.1128/JCM.01510-06 · DOI · Paper page
  98. Musher, 1977, Emergence of variant forms of Staphylococcus aureus after exposure to gentamicin and infectivity of the variants in experimental animals, J Infect Dis, 136, 360, 10.1093/infdis/136.3.360 · DOI
  99. Sendi, 2009, Staphylococcus aureus as an intracellular pathogen: the role of small colony variants, Trends Microbiol, 17, 54, 10.1016/j.tim.2008.11.004 · DOI · Paper page
  100. Cheng, 2011, A play in four acts: Staphylococcus aureus abscess formation, Trends Microbiol, 19, 225, 10.1016/j.tim.2011.01.007 · DOI · Paper page
  101. Hoffman, 2006, Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa, Proc Natl Acad Sci USA, 103, 19890, 10.1073/pnas.0606756104 · DOI · Paper page
  102. Ensminger, 2013, Experimental evolution of pathogenesis: “patient” research, PLoS Pathog, 9, e1003340, 10.1371/journal.ppat.1003340 · DOI

Cited by

See all 197

Metadata

Authors
Geisinger, E., & Isberg, R. R.
Venue
The Journal of Infectious Diseases
Published
2017-02-15
Volume
215
Issue
suppl_1
Pages
S9-S17
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2598043550
Cited by
197
References
6
FWCI
6.10
Type
journal article
Language
en
Open access
green
Funders
  • National Institute of Allergy and Infectious Diseases
  • Howard Hughes Medical Institute (F32-AI098358, U01-AI124302)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria. https://app.cochat.ai/papers/10.1093/infdis/jiw402
The paper
Geisinger, E., & Isberg, R. R. (2017). Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiw402

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.